The role of medroxyprogesterone acetate (MPA) in the treatment of renal adenocarcinoma
- 30 September 1988
- journal article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 15 (3) , 195-209
- https://doi.org/10.1016/0305-7372(88)90003-5
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Nuclear androgen receptor as marker of responsiveness to medroxyprogesterone acetate in human renal cell carcinomaJournal of Steroid Biochemistry, 1981
- The Endocrine Background of Human Renal Cell CarcinomaUrologia Internationalis, 1979
- Renal Cancer Steroid Receptors: Biochemical Basis for Endocrine TherapyEuropean Urology, 1979
- Human kidney steroid receptorsThe Journal of Steroid Biochemistry and Molecular Biology, 1976
- 176. Steroid hormone receptors in human renal carcinomaJournal of Steroid Biochemistry, 1974
- Hormonal therapy of renal carcinoma alone and in association with cytostatic drugsCancer, 1974
- Hormone-induced and spontaneous regression of metastatic renal cancerCancer, 1973
- Medroxyprogesterone Acetate (Provera) in the Treatment of Metastatic Renal CancerBritish Journal of Cancer, 1971
- Hormone-Dependent Tumours of the KidneyBritish Journal of Cancer, 1963
- SPONTANEOUS REGRESSION OF HYPERNEPHROMASActa Pathologica Microbiologica Scandinavica, 1950